(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 7 September 2001 (07.09.2001)

PCT

(10) International Publication Number WO 01/64110 A1

(51) International Patent Classification⁷: A61B 10/00, A61K 31/54

(21) International Application Number: PCT/US00/05387

(22) International Filing Date: 28 February 2000 (28.02.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant (for all designated States except US): ZILA, INC. [US/US]; 5227 North 7th Street, Phoenix, AZ 85014-2800 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BERNAL, Samuel, D. [US/US]; 20000 Calvert Street, Woodland Hills, CA 91367 (US). BURKETT, Douglas, D. [US/US]; 4736 E. Euclid, Phoenix, AZ 85044 (US). GREEN, Ralph, E. [US/US]; 9295 E. Karen Drive, Scottsdale, AZ 85260 (US).

- (74) Agent: DRUMMOND, William, H.; Drummond & Duckworth, Suite 500, 4590 MacArthur Boulevard, Newport Beach, CA 92660 (US).
- (81) Designated States (national): AU, BR, CA, CN, CZ, HU, IL, IN, JP, KR, MX, NO, NZ, PL, RO, SG, SK, TR, UA, US, ZA.
- (84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

01/64110 A

(54) Title: METHOD FOR DETECTING AND KILLING EPITHELIAL CANCER CELLS

METHOD FOR DETECTING AND KILLING EPITHELIAL CANCER CELLS

Field of the Invention

This invention relates to methods for detecting epithelial cancer.

In another respect the invention pertains to methods for selectively killing epithelial cancer cells.

In a further aspect, the invention concerns methods for detecting epithelial cancer cells in the presence of normal cells and/or for selectively killing such cells, in which the mitochondria of cancer cells retains a mitochondrial marking agent for a time sufficient to permit identification and/or killing such cells.

Definitions

As used herein, the following terms have the indicated meanings:

//

11

-2-

"Cancer" or "cancerous" cells are used in the broad sense, to include invasive cancer cells, cancer-insitu cells and severely dysplastic cells.

"Mitochondrial marking agent" means a compound that is selectively taken up by the mitochondria of living cancer cells and is selectively retained in cancer cells for a time sufficient to permit identification and/or killing or incapacitation thereof.

"Killing" of cells means either causing cell death or cell changes that render a cell incapable of reproduction and metastasizing.

"Adduct" means the reaction product of a mitochondrial marking agent and a cancer chemotherapeutic agent.

Background of the Invention

In-vivo diagnostic procedures for detecting malignant and premalignant epithelial lesions or carcinomas, employing dye compositions that selectively

-3-

"color" tissues that are abnormal due to dysplasia,
hyperplasia, tumorigenesis and other active surface
lesions, are known in the art. These diagnostic methods
employ a dye that imparts color to a cancerous substrate,
which is then detectable under light at visible
wavelengths or a fluorescent dye that imparts color to
the substrate, which is then detectable when illuminated
by light at wavelengths outside the visible spectrum.

For example, procedures employing fluorescein and fluorescein derivatives are disclosed in Chenz, Chinese Journal of Stomatology (27:44-47 (1992)) and Filurin (Stomatologiia (Russian) 72:44-47 (1993)). These procedures involve application of the dye, followed by examination under ultraviolet light to detect the cancerous/precancerous tissue, which is selectively fluorescent. Another prior art procedure involves rinsing the epithelium with toluidine blue, followed by normal visual examination to detect any selectively stained tissue. Such procedures are disclosed, for example in the patents to Tucci et al. (U.S. Patent 5,372,801) and Mashberg (U.S. Patent 4,321,251). Use of certain other thiazine dyes and oxazine dyes in an analogous manner is disclosed in U.S. Patent 5,882,627

-4-

to Pomerantz.

Heretofore, it was theorized that such dyes selectively "marked" cancerous tissue because it was retained in the relatively larger interstitial spaces between the cells of cancerous tissue and would not efficiently penetrate the normally tight intracellular junctions of normal tissue or be selectively retained in such relatively smaller spaces.

Contrary to the belief that toluidine blue selectively marks cancerous epithelial tissue because it is selectively retained in the relatively larger interstitial spaces between cancer cells, the mechanism of such selective staining of epithelial tissue by cationic dyes, e.g., dyes such as rhodamine, fluoresceins, oxazine and thiazine dyes (including toluidine blue) and other cationic supravital marking agents is the selective uptake and selective retention of the agent in the mitochondria of cancer cells. In turn, this selective staining of and retention in the mitochondria is apparently due to the higher electrical potential (negative charge on the inside of the membrane) of cancerous mitochondrial cells as compared to normal

-5-

cells. See, e.g., Chen et al., Cancer Cells 1/The
Transformed Phenotype, 75-85 (Cold Spring Harbor
Laboratory, 1984); Lampidis, et al., Cancer Research 43,
716-720 (1983).

In fact, the selective marking and retention of the mitochondria of cancer cells by supravital cationic dyes and other supravital cationic marking agents are related to one of the very characteristics of cancer cells that appears to be responsible for their rapid cloning growth and metastasizing ability, namely, that the higher electrical potential of the mitochondria of cancer cells is the source of cellular energy and is the driving force for ATP (adenosine triphosphate) product of the cells.

Summary of the Invention

I have now discovered a method for in-vivo detection of cancerous epithelial cells by selective marking of the mitochondria thereof. My method comprises the steps of delivering to tissue in the locus of a suspect cancerous site on the epithelium (which contains both normal and cancerous cells), with a cationic supravital mitochondrial marking agent other than rhodamine, causing

said agent to be taken up and selectively retained in the mitochondria of cancer cells. The cancerous cells are then detectable by any suitable method, for example, instrumental or visual examination under visible light or under light of selected invisible wavelengths.

In a further embodiment, after the marking agent is taken up by the mitochondria, a rinse reagent is applied to the locus of the suspect cancerous site, thus enhancing the rate of release of the agent from the mitochondria of the normal cells and further increasing the selectivity of the diagnostic method.

According to another embodiment of the invention, I provide a method for selectively killing cancerous epithelial cells comprising the step of contacting cancerous cells in the locus of a suspect cancerous site with a cationic supravital mitochondrial marking agent, to cause cell death or to render the cancer cells substantially incapable of multiplication. The marking agent can be delivered to the cancer cells in a single discrete dose, or continuously, or in repeated discrete doses, with or without employing a rinse reagent after each dose.

In a further embodiment of the invention, I provide a method of improving the selectivity of cancer chemotherapeutic agents comprising the steps of forming an reaction product of a cationic supravital agent and a chemotherapeutic agent and delivering the reaction product to cancerous epithelial cells.

These, other and further embodiments of the invention will be apparent to those skilled in the art and a better understanding of the invention will be obtained from the following examples which are provided to illustrate the invention and not as indications of the scope thereof, which is defined only by the appended claims.

In the following working examples, cationic supravital mitochondrial marking agents, including

dyes, including toluidine blue O, alcian blue, malachite green, phenosafranin, acriflavine, pyronine Y, toluylene blue and brilliant green;

and

"non-dye" compounds, including peonidin, oxythiamine, tiemonium iodide, elliptinium acetate and furazolium chloride.

In order to be selectively absorbed and retained in cancer cell mitochondria, the marking agent or reaction product of marking agent + chemotherapeutic agent, must have a molecular weight of below about 5,000.

Example 1

Uptake and Retention of Mitochondrial Marking Agents in Living Carcinoma Cells

Different concentrations of the various cationic marking agents, at 100, 50, 10 and 1 µg/ml are prepared in RPMI medium complete with 20% fetal calf serum, 1 mM glutamine, hydrocortisone, insulin, transferrin, estradiol, selenium and growth hormone.

The carcinoma cells are incubated at 37°C in tissue culture incubators with 5% CO₂ and 95% relative humidity, for 5 minutes with each agent and concentration there and then rinsed twice using 2 minute incubations with 1% acetic acid. After incubation and rinsing, the cells are

-9-

harvested, at 30 min., 1 hour, 2 hours, 4 hours and 8 hours. The cells are then extracted with 2-butanol and analyzed by spectrophotometry for quantitation of the marking agent.

The results show that there is a concentration dependence in the rate of accumulation of marking agent in the mitochondria of both carcinoma and normal cells and in the selectivity of release of the marking agent from cancer cells, but this concentration dependence starts to become less pronounced. The saturation concentration for toluidine blue 0 occurs at concentrations of 10µg/ml and above. The saturation concentrations for the other marking agents are similarly determined. The remaining experiments are conducted with a concentration of 10µg/ml for toluidine blue 0 and at the saturation concentrations for the other marking agents so-determined, unless stated otherwise.

Example 2 Mitochondrial Localization of the Agents in Living Cells

After incubation and rinsing of various cell lines, using the different cationic marking agents, the mitochondrial localization of the agents is analyzed

-10-

using confocal high resolution microscopy and phase contrast microscopy.

Living cells, are cultivated in complete growth medium with 20% fetal calf serum and growth factors, and maintained at 37°C. These cells accumulate and retain the marking agents in the mitochondria. When these cells are then maintained in a agent-free medium, carcinoma cells retain the agent for longer than about 1 hour, but normal epithelial cells release the agent within about 15 minutes.

In contrast to living cells, dead cells or cells treated with agents that dissipate the mitochondrial membrane potential lose mitochondrial staining and accumulate the agents in the nucleus.

Example 3

Release of the Agents from Mitochondria With Dissipation of the Mitochondrial Membrane Potential

Known agents that alter the mitochondrial electrical potential are used to pretreat epithelial cancer cells, followed by treatment with the cationic supravital

-11-

mitochondrial marking agents. These pretreatment agents include azide and cyanide preparations and dinitrophenol.

Epithelial cancer cells are also pre-stained with the various dyes and then are post-treated with these known agents. The release of the dyes from the cells or the transfer of the dyes to other subcellular compartments, including the nucleus is analyzed.

The cells pretreated with these agents did not accumulate dyes in the mitochondria and the mitochondria of the pre-stained cells released the dye upon post-treatment with these agents.

Example 4

Tissue Explants of Squamous Carcinomas

Fresh explants of resected epithelial carcinomas are analyzed for marking agent uptake and retention. After resection, the carcinomas are microdissected from surrounding tissue, cut into 3 mm sections and maintained as explant tissue cultures at 37°C. These explants are then incubated with the various agents and then extracted for quantitation of the agent.

-12-

Oral carcinoma (SqCHN) have rapid uptake and prolonged retention of these agents. The agents start to be released from the cells after about one hour of cultivation in agent-free medium. However, the agents are released faster when the cells are incubated in medium that does not contain growth factors, fetal calf serum and other medium additives. The agents are also released faster when the cells are grown in adverse conditions such as lower temperatures.

Example 5

Tissue Explants of Normal Epithelial Cells

Cells obtained surgically from normal areas of the oral epithelium are cultivated as normal epithelial cultures. These cultures are then incubated with the marking agents for analysis of the agent uptake and retention.

Unlike the carcinoma cells, normal epithelial cells quickly release the agents from their mitochondria and from the cell much more quickly. By 10-15 minutes, most of the agent is released from the mitochondria.

-13-

Example 6

Marking Agent-Chemotherapeutic Agent Adducts

In place of the agents of Examples 1-5, the following adducts of cationic mitochondrial marking agents and various known chemotherapeutic agents are employed, with substantially similar results, except that the cancer cell kill rate and selectivity of the chemotherapeutic agent substantially improved.

<u>Marking Agent</u>

toluidine blue 0

rhodamine 123

Chemotherapeutic Agent

methotrexate

nitrogen mustard

-14-

CLAIMS:

Having described my invention in such manner as to enable those skilled in the art to understand and practice it and, having identified the presently preferred embodiments thereof, I CLAIM:

-15-

- 1. A diagnostic method for in vivo detection of cancerous eptithelial cells by selective marking of the mitochondria thereof, comprising the step of delivering to the epithelium a cationic supravital mitochondrial marking agent.
- 2. A method for selective killing of epithelial cancer cells comprising the step of delivering to epithelial cancer cells a cationic supravital mitochondrial marking agent.
- 3. The method of claim 2 in which the agent is the reaction product of a cationic supravital mitochondrial marking agent and a cancer chemotherapeutic drug.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/05387

US 5,372,801 A (MALMROS et al.) 13 December 1994, see Clumms 1-2. US 5,372,801 A (MALMROS et al.) 13 December 1994, see columns 1-2. US 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 1-23, a mitochondrial-specific dye. Science. October 1983, Vol. 222, pages 169-172, entire document. Further documents are listed in the continuation of the science of personal strains or which as obscience of personal strains or which as obscience of personal strains or which the specific dye. Science. October 1983, Vol. 23 JUS 23, 30 Mitochondrial-specific dye. Science. October 1983, Vol. 24 Just 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. Special engages of signal documents of the signal strains or which as obscience in the signal strains of the signal strains or which as the second of the signal strains or shall support date document specified of the signal strains or shall support date document specified to contact a strain or shall support date document on the support date document of the signal strains or shall support date document on the support date document specified to the signal strains or shall support date document specified to the signal strains or shall support date document specified to the signal strains or shall support date document specified to the signal strains or shall support date document specified to the signal strains or shall support date document specified to the signal strains or shall support date document specified to the signal strains of the signal strains of the signal strains or shall support date document specified to the signal strains of the signal strains or shall support date document specified to the signal strains or shall support date document specified to the signal strains or shall support date document specified to the signal strains and strains of the signal strains and strains and	A. CLASSIFICATION OF SUBJECT MATTER				
According to International Patent Classification (IPC) or to hoth national classification and IPC ### FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S.: 4249.6, 9.7, 9.8; 514/222.2, 226.2, 226.8, 227.5, 258; 435/371; 436/64, 800, 813 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched decided as base consulted during the international search (name of data base and, where precisible, search terms; used) APS, CAPLUS, MEDLINE, EMBASE peach terms; epithelial, microbonodrial, carcinoma, cancer, toluidine blue, rhodamine, chemotherapy, imaging ### C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. ### U.S. 5,372,801 A (MALMROS et al.) 13 December 1994, see columns 1-2. ### U.S. 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. ### BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science. October 1983, Vol. 222, pages 169-172, entire document. ### December of the patients of the state of the entire to which a control activity of the protection of cancer to a report protection on a color to the protection of cancer to a report protection on a color to which a control activity of the protection of cancer to a report protection on a color to which a control activity of the protection of cancer to a report protection of the color activity of the protection of cancer to a report protection on a color to the color activity of the protection of cancer to a protection of the color activity of the international decides of state of the color activity of the international decides of state of the color activity of the international search color activity of the international search report activity of the international search report activity of the international search report of the cancer activity of the international search rep	IPC(7) :A61B 10/00; A61K 31/54				
Minimum documentation searched (classification system followed by classification symbols) U.S.: 42496, 9.7, 98; 514(222.2, 226.2, 226.8, 227.5, 258; 435/371; 436/64, 800, 813 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched like the search terms used) APS, CAPLUS, MEDLINE, EMBASE search terms: epithelial, mitochondrial, certiforma, cencer, tolaridine blue, rhodamine, chemotherapy, imaging C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages X. U.S. 5,372,801 A (MALMROS et al.) 13 December 1994, see columns 1-2. Y. U.S. 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. X. BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 1-2. 123, a mitochondrial-specific dye. Science. October 1983, Vol. 222, pages 169-172, entire document. **Special estigatum of safet documents tasts of the state which is not considered to be objected from the policieus of the submensional filing date of the section document which may prove debute as promy elaborate or the submension date of smother trainers or shorts when the section of the submension date of smother trainers or color special relevance in a protection. **Special estigatum of safet documents tasts of the safety of the submension of the s					
Minimum documentation searched (classification system followed by classification symbols) U.S.: 424/9.6, 97, 98, \$14/2222, 226.2, 226.8, 227.5, 238, 435/371; 436/4, 800, 813 Documentation searched other than minimum documents onto the extent that such documents are included in the fields searched the common searched during the international search (name of data base and, where practicable, search terms used) APS. CAPLUS, MEDLINE, EMBASE search terms: epithelial, mitochondrial, carcinoma, cancer, tolisidine blue, thodamine, chemotherapy, imaging C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. U.S. 5,372,801 A (MALMROS et al.) 13 December 1994, see columns 1-2. Y. U.S. 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science. October 1983, Vol. 222, pages 169-172, entire document. Further documents are listed in the continuation of Box C. See patent family abnox. Special segents of fined documents on the season of the segment of the segment of the segment of the season of the segment of the segmen					
Documentation a searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, CAPLUS, MEDLINE, EMBASE Earch terms: epithetial, minchondrial, curcuroma, cancer, toluidine blue, thodamine, chemotherapy, imaging C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. US 5,372,801 A (MALMROS et al.) 13 December 1994, see columns 2-4. US 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. A BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science. October 1983, Vol. 222, pages 169-172, entire document. Further documents are listed in the continuation of Box C. See patent family since. **Special categories of cited documents to be obtained for the continuation of box on the state of the state					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, CAPLUS, MEDLINE, EMBASE search terms: epithelial, mitochondrial, carcinoma, cancer, toluidine blue, rhodamine, chemotherapy, imaging C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. US 5,372,801 A (MALMROS et al.) 13 December 1994, see columns 1-2. Y. US 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science. October 1983, Vol. 222, pages 169-172, entire document. Further documents are listed in the continuation of Box C. See patent family annex. Trivial and the property data demands of the set which a patent search of the september of the search of the september of the search of the searc					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, CAPLUS, MEDLINE, EMBASE search terms: epithefial, mitochondrial, carciaroma, cancer, tolaidine blue, rhodamine, chemotherapy, imaging C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X US 5,372,801 A (MALMROS et al.) 13 December 1994, see columns 1-2. Y US 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science. October 1983, Vol. 222, pages 169-172, entire document. See patent family annex. ** See patent family annex. ** See admonst published for the fact which a not considered to be of perturbin relevance in classes which are given to easily the published on or fact the uncananoual fling date to be of perturbin relevance. ** ** ** ** ** ** ** ** **	221.3, 230, 430, 430, 613				
APS, CAPLUS, MEDLINE, EMBASE search terms: epithelial, mitochendrial, curcinoma, cancer, toloidine blue, rhodamine, chemotherapy, imaging C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X. US 5,372,801 A (MALMROS et al.) 13 December 1994, see columns 1-2. Y. US 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. X. BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science. October 1983, Vol. 222, pages 169-172, entire document. Special estigators of nield documents. A document efforage the general state of the set which is not counseled to be of purcular relevance on the claim of the common published on or after the uncanonal fling date of the state state to entire the supplement make alone testing the special common published on or after the uncanonal fling date of the claim of the set of the sealth in the publication date of the set of the sealth in the publication date of the set of the sealth in the publication date of the set of the sealth in the publication date of the set of the sealth in the publication of the international search to considered to survive sage when the document is a published on or the uncanonal fling date bett later than the sealth of the publication of the international search to the protocy date changed. Date of the actual completion of the international search to the protocy date changed. Date of mailing of the international search report 13 JUN 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Washington, D.C. 20231 Facsimile No. (703) 305-3230	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
APS, CAPLUS, MEDLINE, EMBASE search terms: epithelial, mitochendrial, curcinoma, cancer, toloidine blue, rhodamine, chemotherapy, imaging C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X. US 5,372,801 A (MALMROS et al.) 13 December 1994, see columns 1-2. Y. US 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. X. BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science. October 1983, Vol. 222, pages 169-172, entire document. Special estigators of nield documents. A document efforage the general state of the set which is not counseled to be of purcular relevance on the claim of the common published on or after the uncanonal fling date of the state state to entire the supplement make alone testing the special common published on or after the uncanonal fling date of the claim of the set of the sealth in the publication date of the set of the sealth in the publication date of the set of the sealth in the publication date of the set of the sealth in the publication date of the set of the sealth in the publication of the international search to considered to survive sage when the document is a published on or the uncanonal fling date bett later than the sealth of the publication of the international search to the protocy date changed. Date of the actual completion of the international search to the protocy date changed. Date of mailing of the international search report 13 JUN 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Washington, D.C. 20231 Facsimile No. (703) 305-3230					
See patent family ainex. Further documents are listed in the continuation of Box C. See patent family ainex. Further documents are listed in the continuation of Box C. See patent family ainex. Further documents are listed in the continuation of Box C. Further documents are listed in the continuation of Box C. Further documents are listed in the continuation of Box C. Further documents are listed in the continuation of Box C. Further documents are listed in the continuation of Box C. Further documents are listed in the continuation of Box C. Further documents are listed in the continuation of Box C. See patent family ainex. Further documents are listed in the continuation of Box C. See patent family ainex. Iter document uphaland after the international filing date of protein precisions are closed to underlying the precision facilities. The document which may throw doubts on precity claims to which a special reasen, as a perfection of all or documents are uphaland prior to be undermoted that of continuation the protein facilities. The document which may throw doubts on precity claims to which a special reasen, as a perfection of the continuation of the same passet family and the protein facilities. The document which may throw doubts on precity claims to which a special reason is a special reason as a perfective for the summer substance as a special reason as a perfect and the summer as a special family and the protein facilities. The document which may throw doubts on precity claims to which a special reason as a perfect with the application of the summer summer as a perfect which as a perfect which as a perfect which are a perfect which as a perfect which are a perfect family and the protein of the summer passet family and the protei					
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X US 5,372,801 A (MALMROS et al.) 13 December 1994, see columns 1-2. Y US 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science. October 1983, Vol. 2222, pages 169-172, entire document. Special susgions of cited document. **A document defined the general total of the net which is not considered to the particular relevance to the state of the search of the particular relevance document which may throw doubts on prietry claims to which is action to establish the published on or size the international fling date document which may throw doubts on prietry claims to which is searched occument which may throw doubts on prietry claims to which is searched occument which may throw doubts on prietry claims to which is searched occument which may throw doubts on prietry claims to which is searched occument which may throw doubts on prietry claims to which is searched occument which may throw doubts on prietry claims to which is searched to involve an investors sipplication of the considered to involve an investors sipplication of the considered to involve an investors sipplication of the search of prietrials investors and investors and investors sipplication of the considered to involve an investors sipplication of the considered to involve and investors sipplication of the considered to involve an investors sipplication of the considered to involve and investors are similar of the architecture of Patients and In					
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. US 5,372,801 A (MALMROS et al.) 13 December 1994, see 1 US 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2- 4. BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science. October 1983, Vol. 222, pages 169-172, entire document. Special estagairs of sited documents document defining the general state of the sit which a not considered to be of particular relevant who have placed as the organization of the passages of the passages of the state of the site of the sit	, and one, and one, and and an arranging				
US 5,372,801 A (MALMROS et al.) 13 December 1994, see columns 1-2. Y US 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science. October 1983, Vol. 222, pages 169-172, entire document. Special cargaries of test documents to be of pertender relevance to document upoblased on or size the international fining date to the of pertender relevance to the of pertender relevance to document upoblased on or size the international fining date to the of pertender relevance to the of pertender relevance to the other pertender to the other to document upoblased of an or size the international filing date to the other pertender relevance to the other pertender of the second to the other pertender relevance to the other pertender to the other to the	C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Columns 1-2. US 4,816,395 A (HANCOCK et al.) 28 March 1989, see columns 2-4. BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science. October 1983, Vol. 222, pages 169-172, entire document. Further documents are listed in the continuation of Box C. 222, pages 169-172, entire document. Special categories of cited do	Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.	
### Purther documents are listed in the continuation of Box C. See patent family aimex. 1-2 3	Х				
Further documents are listed in the continuation of Box C. See patent family annex. ** ** ** ** ** ** ** ** **	Υ		3		
Further documents are listed in the continuation of Box C. See patent family annex. ** ** ** ** ** ** ** ** **	30	DEDNAL C			
Further documents are listed in the continuation of Box C. See patent family annex. **To document defining the general state of the set which is not considered to be of particular relevance to the office particular relevance to the office particular relevance to the office particular relevance to understand the principle or theory underlying the simention contained the principle or theory underlying the simention of the particular relevance to considered one of considered to unvolve an inventive step when the document understand the principle or theory underlying the simention of the contact of establish the publication date of another citation or which is excited to establish the publication date of another citation or other special reason (as specified) **O' document referring to an oral disclosure, use, exhibition or other means **P' document referring to an oral disclosure, use, exhibition or other the principle declarated to unvolve an unventive step when the document is conducted do unvolve an unventive step when the document of particular relevance; the claimed unvention cannot be considered to unvolve an unventive step when the document of particular relevance the claimed unvention cannot be considered to unvolve an unventive step when the document is conducted with one or more other such document; is conducted with one or more other such document; is conducted with one or more other such document; is conducted with one or more other such document; is conducted with one or more other such document. *A' document referring to an oral disclosure, use, exhibition or other means. *B' document published prior to the unternational search *B' document published prior to the unternational search *B' document published files the step when the document is conducted with one or more other such document; is conducted with one or more other such document. *A' document published prior to the unternational search published prior to the unternation cannot be considered to unvolve an unventive step when the docu	X	BERNAL, S. et al. Anticarcinoma activity in vivo of rhodamine 1-2			
Further documents are listed in the continuation of Box C. See patent family annex. To later document published after the international filting date or priority data and not in conflict with the application but end to understand to be of particular relevance. To document published on or after the international filting date. To document published on or after the international filting date. To document published on or after the international filting date. To document published on or after the international filting date. To document published on or after the internation or other entation or other internation or other internation or other internation or other international search in the priority date international date in conflict in the priority date international date of enother considered to understand the priority date international date of enother cannot be considered to understand the priority date international determined in the entire of particular relevance, the claimed unventure expendity and the priority date and not in conflict with the priority date international date of enother cannot be	v				
Special categories of cited documents. A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date. *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means. *P* document published prior to the international search *P* document published prior to the unternational search *O* MAY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 Telephone No. (703) 308-1235 Telephone No. (703) 308-1235 Total document published after the international filing date or priority date and not in conflict with the application but end for understand the principle of theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is combined in the document is combined in the priority date claimed unvention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *2.* document member of the same patent family Date of the actual completion of the international search *3.* document member of the same patent family Date of mailing of the international search report *3.* DYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX Telephone No. (703) 308-1235	1	222, pages 169-172, entire document.			
Special categories of cited documents. A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date. *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means. *P* document published prior to the international search *P* document published prior to the unternational search *O* MAY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 Telephone No. (703) 308-1235 Telephone No. (703) 308-1235 Total document published after the international filing date or priority date and not in conflict with the application but end for understand the principle of theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is combined in the document is combined in the priority date claimed unvention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *2.* document member of the same patent family Date of the actual completion of the international search *3.* document member of the same patent family Date of mailing of the international search report *3.* DYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX Telephone No. (703) 308-1235					
Special categories of cited documents. A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date. *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means. *P* document published prior to the international search *P* document published prior to the unternational search *O* MAY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 Telephone No. (703) 308-1235 Telephone No. (703) 308-1235 Total document published after the international filing date or priority date and not in conflict with the application but end for understand the principle of theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is combined in the document is combined in the priority date claimed unvention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *2.* document member of the same patent family Date of the actual completion of the international search *3.* document member of the same patent family Date of mailing of the international search report *3.* DYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX Telephone No. (703) 308-1235					
Special categories of cited documents. A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date. *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means. *P* document published prior to the international search *P* document published prior to the unternational search *O* MAY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 Telephone No. (703) 308-1235 Telephone No. (703) 308-1235 Total document published after the international filing date or priority date and not in conflict with the application but end for understand the principle of theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is combined in the document is combined in the priority date claimed unvention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *2.* document member of the same patent family Date of the actual completion of the international search *3.* document member of the same patent family Date of mailing of the international search report *3.* DYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX Telephone No. (703) 308-1235					
Special categories of cited documents. A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date. *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means. *P* document published prior to the international search *P* document published prior to the unternational search *O* MAY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 Telephone No. (703) 308-1235 Telephone No. (703) 308-1235 Total document published after the international filing date or priority date and not in conflict with the application but end for understand the principle of theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is combined in the document is combined in the priority date claimed unvention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *2.* document member of the same patent family Date of the actual completion of the international search *3.* document member of the same patent family Date of mailing of the international search report *3.* DYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX Telephone No. (703) 308-1235					
Special categories of cited documents. A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be consid					
Special categories of cited documents. A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be consid					
Special categories of cited documents. A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be consid					
Special categories of cited documents. A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be consid					
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubte on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *Date of the actual completion of the international search O9 MAY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 determined in particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is document with one or more other such document is document with one or more other such document; such combination being obvious to a person skilled in the art *2* document member of the same patent family Date of the actual completion of the international search O9 MAY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 Telephone No. (703) 308-1235	Further documents are listed in the continuation of Box C. See patent family annex.				
detailed designed the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubte on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "P" document published prior to the international search O9 MAY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 document which is not considered to unvolve an inventive step when the document is document in taken alone "X". document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document, such combination being obvious to a person skilled in the art "A". document published prior to the international search Date of mailing of the international search report 13 JUN 2000 Authorized officer JOYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX Telephone No. (703) 308-1235	Special categories of cited documents 'T' later document published after the international films date or process				
**E* earlier document published on or after the international filing date "L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O* document referring to an oral disclosure, use, exhibition or other means "P* document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search O9 MAY 2000 Name and mailting address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 **X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is combined to involve an inventive step when the document is combined to involve an inventive step when the document is combined to involve an inventive step when the document is document of particular relevance; the claimed invention cannot be considered novel or cannot be considered n	"A" document defining the general state of the art which is not considered data and not in conflict with the application but cited to understand the principle of theory underlying the invention				
**O* document published prior to the international search O9 MAY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 when the document is taken alone when the document is taken alone document is taken alone "Y' document of perticular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document. Such combination being obvious to a person skilled in the art age: document member of the same patent family Date of the actual completion of the international search O9 MAY 2000 Authorized officer MICHAEL G. HARTLEY Telephone No. (703) 308-1235 When the document is taken alone document is taken alone when the document is taken alone document is taken alone when the document is taken alone document is taken alone when the document is taken alone document is taken alone when the document is taken alone document is taken alone when the document is taken alone document is taken alone when the document is taken alone document is taken alone document is taken alone when the document is taken alone document is taken alone Telephone to more other such document is document member of the same patent family Date of mailing of the international search report 13 JUN 2000 Authorized officer MICHAEL G. HARTLEY SHEMICAL MATRIX Telephone No. (703) 308-1235		·		s claimed invention cannot be	
special reason (as specified) **Y*** document of perturbing relevance; the claimed inventor cannot be considered to involve an inventor step when the document is combined with one or more other such document, such combination being obvious to a person skilled in the art document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search of MAY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 Telephone No. (703) 308-1235 Authorized officer MICHAEL G. HARTLEY Telephone No. (703) 308-1235			considered novel of cannot be conside when the document is taken alone	red to unvolve an inventive step	
document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 09 MAY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 Combination or other such documents, such combination being obvious to a person skilled in the art document member of the same patent family Date of mailing of the international search report 13 JUN 2000 Authorized officer JOYCE BRUDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX Telephone No. (703) 308-1235				s claumed unvention cannot be	
Date of the actual completion of the international search 09 MAY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 Date of mailing of the international search report 13 JUN 2000 Authorized officer MICHAEL G. HARTLEY Telephone No. (703) 308-1235 Telephone No. (703) 308-1235	me		combined with one or more other such	documents, such combination	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 Authorized officer MICHAEL G. HARTLEY Telephone No. (703) 308-1235 Authorized officer MICHAEL G. HARTLEY CHEMICAL MATRIX Telephone No. (703) 308-1235			*&* document member of the same patent	family	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 Authorized officer MICHAEL G. HARTLEY MICHAEL G. HARTLEY Telephone No. (703) 308-1235 Telephone No. (703) 308-1235					
Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 MICHAEL G. HARTLEY CHEMICAL MATRIX Telephone No. (703) 308-1235	13 JUN 2000				
Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 MICHAEL G. HARTLEY CHEMICAL MATRIX Telephone No. (703) 308-1235			Authorized officer	JOYCE BRIDGERS	
Facsimile No. (703) 305-3230 Telephone No. (703) 308-1235	Box PCT		MICHAEL G. HARTLEY		
	-		/	OFFICIAL MATRIX	
			15.598586 175. (753) 300-1233	J 17 17	